NESINA (alogliptin benzoate)
Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used to manage blood glucose levels in the adult patient population. The medication is not recommended for the treatment of patients with type 1 diabetes mellitus.
How NESINA Works
Alogliptin selectively binds to and inhibits the enzyme DPP-4, which normally inactivates incretin hormones such as GLP-1 and GIP. By slowing this inactivation, the drug increases the bloodstream concentrations of these hormones, which stimulate insulin release from pancreatic beta cells in a glucose-dependent manner. Additionally, increased GLP-1 levels lower glucagon secretion, leading to reduced hepatic glucose production and lower fasting and postprandial glucose concentrations.
Details
- Status
- Prescription
- First Approved
- 2013-01-25
- Patent Cliff
- 2029
- Routes
- ORAL
- Dosage Forms
- TABLET
NESINA Approval History
What NESINA Treats
1 indicationsNESINA is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Type 2 diabetes mellitus
NESINA Target & Pathway
ProTarget
A hormone released after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists mimic these effects, improving blood sugar control and promoting weight loss in diabetes and obesity.
NESINA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in NESINA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications NESINA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to NESINA
3 of 6FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02856113 results posted | SYR-322_309 U1111-1174-1923, 2015-000208-25 | Ph 3 | completed | Phase 3 Alogliptin Pediatric Study |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NESINA FDA Label Details
Indications & Usage
FDA Label (PDF)NESINA is indicated for the treatment of Type 2 diabetes mellitus.
NESINA Patents & Exclusivity
Exclusivity
Pro Intelligence Preview
Deep insights for NESINA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2029
- • 18 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 6 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.